NovaBay Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NovaBay Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $370.0K | Mar 26, 2015 |
| FY2014 | Dec 31, 2013 | $3.25M | Mar 26, 2015 |
| FY2014 | Dec 31, 2012 | $6.93M | Mar 26, 2015 |
| FY2013 | Dec 31, 2011 | $11.02M | Mar 6, 2014 |
| FY2012 | Dec 31, 2010 | $9.75M | Mar 14, 2013 |
| FY2011 | Dec 31, 2009 | $15.68M | Mar 27, 2012 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $18.23M | Mar 21, 2018 |
| FY2017 | Dec 31, 2016 | $11.90M | Mar 21, 2018 |
| FY2017 | Dec 31, 2015 | $4.38M | Mar 21, 2018 |
| FY2016 | Dec 31, 2014 | $1.05M | Mar 23, 2017 |
| FY2015 | Dec 31, 2013 | $3.48M | Mar 4, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.48M | Apr 2, 2025 |
| FY2024 | Dec 31, 2023 | $6.08M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $7.78M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $6.52M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.96M | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | $4.86M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $11.01M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $15.45M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $9.43M | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $3.12M | Mar 21, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.14M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($7.22M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($9.64M) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | ($10.61M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($5.82M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($11.04M) | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | ($9.66M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | ($6.55M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($7.40M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | ($13.15M) | Mar 29, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.44M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($7.38M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($4.10M) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | ($14.42M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($8.86M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.43M) | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | ($9.40M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | ($7.87M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($7.31M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | ($10.98M) | Mar 29, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $42.0K | Apr 2, 2025 |
| FY2024 | Dec 31, 2023 | $34.0K | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $174.0K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $44.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $285.0K | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | $184.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $259.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $410.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.37M | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $5.73M | Mar 21, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $18.09M | Mar 4, 2016 |
| FY2015 | Dec 31, 2014 | $7.94M | Mar 4, 2016 |
| FY2015 | Dec 31, 2013 | $6.34M | Mar 4, 2016 |
| FY2014 | Dec 31, 2012 | $5.97M | Mar 26, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.43M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($7.50M) | Mar 19, 2026 |
| FY2023 | Dec 31, 2023 | ($4.13M) | Mar 26, 2024 |
| FY2023 | Dec 31, 2022 | ($6.65M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($9.19M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.72M) | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | ($7.93M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | ($5.57M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($6.27M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | ($11.66M) | Mar 29, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.0K | Apr 2, 2025 |
| FY2024 | Dec 31, 2023 | $19.0K | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $112.0K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $52.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $26.0K | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | $19.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $44.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $244.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $160.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $123.0K | Mar 21, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.04M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.42M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $9.03M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $16.40M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $23.98M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $15.24M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $11.22M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $9.36M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $10.08M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $15.38M | Mar 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.86M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.55M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $5.72M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $5.85M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $13.81M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.92M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $10.25M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.41M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $7.49M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $8.28M | Mar 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.18M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($129.0K) | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.31M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $10.55M | Apr 2, 2025 |
| FY2023 | Dec 31, 2021 | $10.17M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | $12.32M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $973.0K | Mar 29, 2022 |
| FY2021 | Dec 31, 2018 | $4.95M | Mar 29, 2022 |
| FY2020 | Dec 31, 2017 | $2.59M | Mar 25, 2021 |
| FY2019 | Dec 31, 2016 | $7.10M | Mar 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $0 | Apr 2, 2025 |
| FY2024 | Dec 31, 2022 | $348.0K | Apr 2, 2025 |
| FY2023 | Dec 31, 2021 | $4.53M | Mar 26, 2024 |
| FY2021 | Dec 31, 2020 | $0 | Mar 29, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($210.42M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($183.46M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($174.85M) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | ($158.15M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($141.89M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($136.06M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($125.02M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($114.98M) | Mar 26, 2020 |
| FY2018 | Jan 1, 2018 | ($108.44M) | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | ($111.07M) | Mar 29, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.96M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $430.0K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.92M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $5.36M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $7.50M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $11.95M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $6.94M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.18M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.20M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $9.51M | Mar 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (12) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (139) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | (1) | Mar 29, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 0 | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 25, 2021 |
| FY2020 | Dec 31, 2018 | 0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | (1) | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | (6) | Mar 21, 2018 |
| FY2016 | Dec 31, 2014 | (7) | Mar 23, 2017 |
| FY2015 | Dec 31, 2013 | (10) | Mar 4, 2016 |
| FY2014 | Dec 31, 2012 | 0 | Mar 26, 2015 |
| FY2013 | Dec 31, 2011 | 0 | Mar 6, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.22M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 977,000 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 321,000 | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | 2.04M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 1.37M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 41.78M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 27.94M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 17.09M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 15.39M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 15.27M | Mar 21, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 29, 2025 | $4.80M | Mar 19, 2026 |